Ido Wolf

Head, Oncology Division, Tel Aviv Medical Center; Head, Medical School, Tel Aviv University; Head, Israeli National Council for Malignant Diseases

[Ido Wolf @IdoWolf5]

New findings from our team on metastatic breast cancer: ESR1 mutations not only drives endocrine resistance chemotherapy resistance through downregulation of MDR1.
Kudos to PhD student Marwa Taha for leading this groundbreaking work.

https://t.co/VaNKZZooDP

[Ido Wolf @IdoWolf5]

@ArndtVogel @JCO_ASCO @myESMO We should definitely start.
The risk-benefit ratio is amazing

[Ido Wolf @IdoWolf5]

We must urge our patients to conduct full and meaningful life even during treatments. And even more importantly, we must educate health care workers to stop providing misleading and irrelevant information regarding avoidance behaviour.

[Ido Wolf @IdoWolf5]

Why don’t they go to the beach, don’t meet friends and don’t pet their dog?
We conducted a large digital survey and discovered that too many cancer patients avoid so many daily life activities, but with no good reason.

https://t.co/8uVFQO6HQX

[Ido Wolf @IdoWolf5]

Proud of our recent NEJM-AI paper.
GPT versus Resident Physicians — A Benchmark Based on Official Board Scores.
The chat is doing better than doctors in the board exams. But what does it mean? https://t.co/tN1G9gMEFf

[Ido Wolf @IdoWolf5]

@BiffiGiulia Never 😢

[Ido Wolf @IdoWolf5]

@NicoleFleege In 2012 we submitted to ASCO the first report ever on ESR1 mutations. Quite important one would assume.
Not accepted for presentation!

[Ido Wolf @IdoWolf5]

A new exciting paper from our group. Institutional-Level Monitoring of Immune Checkpoint Inhibitor Side Effect Using a Novel NLP Algorithmic Pipeline.
A critical tool for safety and quality monitoring. https://t.co/02XtJxt7Es

[Ido Wolf @IdoWolf5]

@OncBrothers @VKaklamani @CancerNetwrk @UTHealthSAMDA @stolaney1 @BijoyTelivala @dr_yakupergun @RenoHemonc @gandhi_shipra @matteolambe @ErikaHamilton9 @drteplinsky @BianchiniGP A great algorithm!
One small remark. In the metastatic setting no need to start CDK4/6i to all. Some should start only with endocrine therapy.

[Ido Wolf @IdoWolf5]

סוף סוף פורסמו נתוני תמותה מסרטן בארה״ב בשנת 2021.
הירידה בתמותה נמשכת.

https://t.co/yuNEbYvU20

[Tel-Aviv Université @UniTelAviv]

L' @UniTelAviv rend les études de médecine accessibles à tous les groupes de la population israélienne https://t.co/VrbgFvOzfZ

[Ido Wolf @IdoWolf5]

@IshwariaMD Our paper includes a very clean cohort and lab data including a mouse model.
The results suggest that cannabis does not reduce the efficacy of ici.
It was also presented as ISLAC.

[Ido Wolf @IdoWolf5]

@IshwariaMD This is paper has multiple confounders and some other methodological issues. It was published in Cancers, which does not provide the most thorough peer review process. As this paper caused so much unjustified fear, we published our paper: a sigh of relief

https://t.co/2pjZ5QNaqY

[Ido Wolf @IdoWolf5]

הישג אמיתי וחשוב למערכת הבריאות ובעיקר לחולים. בשעה טובה אושר תואר מומחה בסיעוד בכמה תחומים קריטיים ובהם אונקולוגיה. זו דרך מעולה להקל על מצוקת המערכת.

[Ido Wolf @IdoWolf5]

Two minutes and simple H&E slide is all we need to identify EGFR mutations in NSCLC https://t.co/VFFYgJiZcV

[Ido Wolf @IdoWolf5]

@DKarikios In Israel it is also reimbursed only once for a patient

[Ido Wolf @IdoWolf5]

It’s great to see our work at the top stories of Medscape. https://t.co/hp68uky9v6

[Ido Wolf @IdoWolf5]

Diabetic patients with NSCLC do not respond well to immunotherapy.
Should we avoid single agent immunotherapy in these patients? https://t.co/DKJUVBg0Xt

[Ido Wolf @IdoWolf5]

So proud, an extremely important observation of our group.
We show, for the first time, that diabetes may interfere with the activity of immunotherapy.
If validated by other groups as well, it may be practice changing. https://t.co/5n0cWYiLgo

[Ido Wolf @IdoWolf5]

@montypal @GlopesMd Absolutely, not only in the US, also in Israel